Novo Nordisk (NVO) stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share on $11.92 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?Analysts polled by FactSet expected Novo to earn 83 cents a share on $11.14 billion in sales.
In the year-earlier period, Novo earned 72 cents a share and had $9.6 billion in sales.
Wegovy, the company's obesity drug, generated $2.77 billion in sales, just shy of expectations for $2.78 billion. Ozempic, the diabetes treatment that uses the same semaglutide active ingredient, brought in $4.77 billion in sales. That beat forecasts for $4.59 billion.
For the year, Novo Nordisk guided to 16% to 24% sales growth, excluding the impact of exchange rates. However, Novo noted the outlook includes expectations for "continued periodic supply constraints and related drug shortage notifications across a number of products and geographies." The Street projected earnings of $3.82 per share and $48.18 billion in sales.
In premarket trades on the stock market today, Novo Nordisk stock jumped 4% to 85.91.
More to follow.
YOU MAY ALSO LIKE:
Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Join IBD Live For Stock Ideas Each Morning Before The Open
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。